Treatment of juvenile rheumatoid arthritis.
New information on the treatment of juvenile rheumatoid arthritis emphasizes more aggressive control of arthritis, particularly the use of methotrexate, both in low- and higher-dose regimens. Information concerning drug toxicity, including that of the nonsteroidal anti-inflammatory drugs, second-line agents, and methotrexate, suggests that these drugs are well tolerated in children. A new corticosteroid, deflazacort, minimizes bone demineralization and growth retardation. Adjunctive measures, including erythropoietin, pain management techniques, conditioning programs, and nutrition, have demonstrated advantages in some children with juvenile rheumatoid arthritis.
Emery
H M
HM
Department of Pediatrics, University of California, San Francisco 94143.
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001171:Arthritis, Juvenile / Q000188:drug therapy*; D002648:Child; D004921:Erythropoietin / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D009747:Nutritional Physiological Phenomena; D059408:Pain Management; D011282:Pregnenediones / Q000627:therapeutic use; D012460:Sulfasalazine / Q000627:therapeutic use; D005719:gamma-Globulins / Q000627:therapeutic use
D000894:Anti-Inflammatory Agents, Non-Steroidal; D005938:Glucocorticoids; D011282:Pregnenediones; D005719:gamma-Globulins; D004921:Erythropoietin; D012460:Sulfasalazine; D006886:Hydroxychloroquine; C021988:deflazacort; D008727:Methotrexate